Siemens Healthineers today posted mixed second-quarter results that included a reduced outlook for the full financial year.
The company said that a structural change in the Chinese diagnostics market and more pronounced inflation assumptions during the quarter caused the change in guidance for 2026. After projecting between 5% and 6% sales growth and adjusted earnings per share (EPS) between $2.59 and $2.83, the company now expects growth between 4.5% and 5% and adjusted EPS between $2.59 and $2.71.
”While the environment remains tough, our synergetic core of Imaging and Precision Therapy is on track with good momentum. We are also taking measures for the future of the company by initiating the next steps to create options for Diagnostics and introducing an evolution of the leadership team,” said Siemens Healthineers CEO Bernd Montag.
Montag announced the company’s leadership changes in a LinkedIn post published on Thursday.
Shares of Siemens Healthineers fell 5% to on the XETRA yesterday following the earnings news.
The Germany-based medtech company reported profits of $602.7 million. That equals 53¢ per share on sales of $6.7 billion for the three months ended March 31, 2026.
Siemens Healthineers recorded a 4.7% bottom-line slide on a sales decrease of 3.9%.
Adjusted to exclude one-time items, earnings per share came in at 62¢. That landed 2¢ ahead of expectations on Wall Street. However, sales fell shy of estimates, with experts projecting $7.06 billion in revenue.
The company’s Diagnostics business saw revenue fall 6.5% as a result of the Chinese market conditions. Imaging grew 6.1% and Precision Therapy increased 4.7% year over year.
More on Siemens Healthineers leadership changes
Andreas Schneck will take over as head of diagnostic imaging on June 1, succeeding André Hartung, who “decided to leave the company after 25 years to pursue other opportunities.” Schneck has held various leadership roles across the company’s diagnostic and interventional imaging segment.
Philipp Fischer will become head of advanced therapies on June 1, succeeding a retiring Carsten Bertram. Bertram will support Siemens’ new chief technology officer, Martin Stumpe, until 2027.
Sonja Wehsely will take over as head of the company’s Europe, Middle East and Africa segment on June 1, replacing Bernd Ohnesorge, who led the segment for the past eight years. Ohnesorge “decided to step aside for personal reasons,” Montag said in the post, but will continue to serve as a senior advisor to the managing board.
Elaine Becraft will be promoted to chief human resources officer on October 1. Becraft currently leads human resources for the company’s diagnostics segment.
Meanwhile, the company still looks to stand alone as parent company Siemens announced plans last year to deconsolidate its remaining stake in Siemens Healthineers.
Associate Editor Skyler Rivera contributed reporting. This story originally ran on May 7, 2026. Updated May 8 with the leadership change news.
